Javascript must be enabled to continue!
Adherence to Statin Therapy Among US Adults Between 2007 and 2014
View through CrossRef
Background
Prior studies suggest that persistence with and adherence to statin therapy is low. Interventions to improve statin persistence and adherence have been developed over the past decade.
Methods and Results
This was a retrospective cohort study of adults aged ≥21 y with commercial or government health insurance in the MarketScan (Truven Health Analytics) and Medicare databases who initiated statins in 2007–2014 and (1) started treatment after a myocardial infarction (n=201 573), (2) had diabetes mellitus but without coronary heart disease (CHD; n=610 049), or (3) did not have CHD or diabetes mellitus (n=2 244 868). Persistence with (ie, not discontinuing treatment) and high adherence to statin therapy were assessed using pharmacy fills in the year following treatment initiation. In 2007 and 2014, the proportions of patients persistent with statin therapy were 78.1% and 79.1%, respectively, among those initiating treatment following myocardial infarction; 66.5% and 67.3%, respectively, for those with diabetes mellitus but without CHD; and 64.3% and 63.9%, respectively, for those without CHD or diabetes mellitus. Between 2007 and 2014, high adherence to statin therapy increased from 57.9% to 63.8% among patients initiating treatment following myocardial infarction and from 34.9% to 37.6% among those with diabetes mellitus but without CHD (each
P
trend
<0.001). Among patients without CHD or diabetes mellitus, high adherence did not improve between 2007 (35.7%) and 2014 (36.8%;
P
trend
=0.14). In 2014, statin adherence was lower among younger, black, and Hispanic patients versus white patients and those initiating a high‐intensity statin dosage. Statin adherence was higher among men and patients with cardiologist care following treatment initiation.
Conclusions
Persistence with and adherence to statin therapy remain low, particularly among those without CHD.
Ovid Technologies (Wolters Kluwer Health)
Title: Adherence to Statin Therapy Among US Adults Between 2007 and 2014
Description:
Background
Prior studies suggest that persistence with and adherence to statin therapy is low.
Interventions to improve statin persistence and adherence have been developed over the past decade.
Methods and Results
This was a retrospective cohort study of adults aged ≥21 y with commercial or government health insurance in the MarketScan (Truven Health Analytics) and Medicare databases who initiated statins in 2007–2014 and (1) started treatment after a myocardial infarction (n=201 573), (2) had diabetes mellitus but without coronary heart disease (CHD; n=610 049), or (3) did not have CHD or diabetes mellitus (n=2 244 868).
Persistence with (ie, not discontinuing treatment) and high adherence to statin therapy were assessed using pharmacy fills in the year following treatment initiation.
In 2007 and 2014, the proportions of patients persistent with statin therapy were 78.
1% and 79.
1%, respectively, among those initiating treatment following myocardial infarction; 66.
5% and 67.
3%, respectively, for those with diabetes mellitus but without CHD; and 64.
3% and 63.
9%, respectively, for those without CHD or diabetes mellitus.
Between 2007 and 2014, high adherence to statin therapy increased from 57.
9% to 63.
8% among patients initiating treatment following myocardial infarction and from 34.
9% to 37.
6% among those with diabetes mellitus but without CHD (each
P
trend
<0.
001).
Among patients without CHD or diabetes mellitus, high adherence did not improve between 2007 (35.
7%) and 2014 (36.
8%;
P
trend
=0.
14).
In 2014, statin adherence was lower among younger, black, and Hispanic patients versus white patients and those initiating a high‐intensity statin dosage.
Statin adherence was higher among men and patients with cardiologist care following treatment initiation.
Conclusions
Persistence with and adherence to statin therapy remain low, particularly among those without CHD.
Related Results
GAMBARAN PROFIL LIPID PADA PASIEN PENYAKIT JANTUNG KORONER
GAMBARAN PROFIL LIPID PADA PASIEN PENYAKIT JANTUNG KORONER
Abstract: Coronary Heart Disease is a heart disease caused by the narrowing of the coronary arteries, which then disturbs the flow of blood to the myocardium. The result of SKRT do...
Predictors of statin adherence in primary care using real-world data
Predictors of statin adherence in primary care using real-world data
Abstract
Purpose
The objective of this study was to identify predictors of statin adherence in the primary and secondary preven...
A Link Between Hypercholesterolemia and Chronic Lymphocytic Leukemia
A Link Between Hypercholesterolemia and Chronic Lymphocytic Leukemia
Abstract
Background
Dyslipidemia and metabolic syndrome are risk factors for cancer, and clinically aggressive CLL cells are believed to rely on lipid...
Abstract MP76: Trends in Adherence to Statin Therapy Among US Adults With Health Insurance Between 2007 and 2014
Abstract MP76: Trends in Adherence to Statin Therapy Among US Adults With Health Insurance Between 2007 and 2014
Background:
Statins are effective for the primary and secondary prevention of coronary heart disease (CHD) events. However, studies from the early 2000s have suggested ...
Abstract P1-15-03: Assessing the association of statins with clinical outcomes in women with breast cancer
Abstract P1-15-03: Assessing the association of statins with clinical outcomes in women with breast cancer
Abstract
Background: A growing number of studies are claiming lipid-lowering medications (LLMs) primarily statins have anticancer properties to inhibit proliferation...
Fat-Free Mass and Fasting Glucose Values in Patients with and without Statin Therapy Assigned to Age Groups between <60 and >75 Years
Fat-Free Mass and Fasting Glucose Values in Patients with and without Statin Therapy Assigned to Age Groups between <60 and >75 Years
<b><i>Objective:</i></b> The aging-associated changes in body composition result in an increased cardiometabolic risk. A tremendous reduction of cardiovascu...
1228-P: Comparison between Combination of Low- or Moderate-Intensity Statin with Ezetimibe and High-Intensity Statin Monotherapy for Primary Prevention of Cardiovascular Disease and All-Cause Mortalities in Patients with Type 2 Diabetes—A Propensity-Match
1228-P: Comparison between Combination of Low- or Moderate-Intensity Statin with Ezetimibe and High-Intensity Statin Monotherapy for Primary Prevention of Cardiovascular Disease and All-Cause Mortalities in Patients with Type 2 Diabetes—A Propensity-Match
Background and Aims: Here, we compared the effects of combination therapy of low- or moderate-statin with ezetimibe and high-intensity statin monotherapy in patients with type 2 di...
Statins Are Associated with Improved 28-day Mortality in Patients Hospitalized with SARS-CoV-2 Infection
Statins Are Associated with Improved 28-day Mortality in Patients Hospitalized with SARS-CoV-2 Infection
Abstract
Background
Statins may be protective in viral infection and have been proposed as treatment in severe acute respirator...

